\n \n 7 May 2021\n \n
\n\n \n \n \n\n \n \n \nSix scientists from the University of Oxford have joined the Royal Society as Fellows
\n \n\n\n \n 23 April 2021\n \n
\n\n \n \n \n\n \n \n \nData from the national COVID-19 Infection Survey, which is led by senior NIHR Oxford BRC researcher Professor Sarah Walker, has revealed the impact of vaccination on antibody responses and new infections in a large group of adults from the general population
\n \n\n\n \n 6 April 2021\n \n
\n\n \n \n \n\n \n \n \nThe new easy-to-produce test detects coronavirus spike-protein binding antibodies in people who have tested positive for COVID-19
\n \n\n\n \n 23 March 2021\n \n
\n\n \n \n \n\n \n \n \nThe Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial
\n \n\n\n \n 22 March 2021\n \n
\n\n \n \n \n\n \n \n \nA Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom
\n \n\n\n \n 5 March 2021\n \n
\n\n \n \n \n\n \n \n \nNDM's Professor Sarah Gilbert has been awarded the Royal Society for Arts\u2019 (RSA) Albert Medal for her work on the Oxford vaccine. Professor Gilbert is Professor of Vaccinology and the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world
\n \n\n\n \n 18 February 2021\n \n
\n\n \n \n \n\n \n \n \nThe Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world\u2019s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join and recruited to RECOVERY International. NDM's Peter Horby, Professor of Emerging Infectious Diseases and Global Health, and Joint Chief Investigator for the trial, said \u2018The RECOVERY trial has been an enormous success, enrolling over 36,000 patients and delivering clear results on six treatments already. By building on this success through international partnership we can speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies\".
\n \n\n\n \n 12 February 2021\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 10 February 2021\n \n
\n\n \n \n \n\n \n \n \nEarly treatment with a medication commonly used to treat asthma appears to significantly reduce the need for urgent care and hospitalisation in people with COVID-19, researchers at the University of Oxford have found
\n \n\n\n \n 21 January 2021\n \n
\n\n \n \n \n\n \n \n \nResearchers from NDM's Big Data Institute working with Public Health England and NHS Test and Trace, have used Test and Trace data to find out why some individuals pass COVID-19 on to their contacts more easily than others, and if lateral flow tests are sufficient in detecting those who are most infectious
\n \n\n\n \n 19 January 2021\n \n
\n\n \n \n \n\n \n \n \nA new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with \u00a32.5 million funding from UK Research and Innovation (UKRI)
\n \n\n\n \n 30 December 2020\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford welcomes the news that the UK Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine in the UK
\n \n\n\n \n 21 December 2020\n \n
\n\n \n \n \n\n \n \n \nFrom a small discovery to producing at scale, photojournalist David Levene documents the groundbreaking work of the scientists of Oxford University during the development of a vaccine which is now poised for approval by medicines regulators
\n \n\n\n \n 14 December 2020\n \n
\n\n \n \n \n\n \n \n \nRECOVERY reports absence of a benefit from Azithromycin. The latest result from the NDM/NDPH RECOVERY trial shows the widely administered administration of a broad-spectrum antibiotic makes no difference to the routine outcome in hospitalised COVID19 disease. Results on other therapies are likely to follow in the coming weeks.
\n \n\n\n \n 11 December 2020\n \n
\n\n \n \n \n\n \n \n \nData from the National COVID-19 Infection Survey, done in partnership between the University of Oxford, the Office of National Statistics, Public Health England, University of Manchester and the Wellcome Trust, has revealed detailed characteristics of England\u2019s coronavirus pandemic, including which factors have contributed most to case numbers over different phases and the prevalence of asymptomatic infections.
\n \n\n\n \n 9 December 2020\n \n
\n\n \n \n \n\n \n \n \nToday, the University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%. The new study published in the Lancet is the first peer-reviewed publication of phase 3 data from studies of a vaccine against the coronavirus.
\n \n\n\n \n 29 November 2020\n \n
\n\n \n \n \n\n \n \n \nOxford vaccine heroes reveal pride at cracking Covid jab in just nine months
\n \n\n\n \n 23 November 2020\n \n
\n\n \n \n \n\n \n \n \nThe University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.
\n \n\n\n \n 20 November 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n\n \n 11 November 2020\n \n
\n\n \n \n \n\n \n \n \n \n \n\n